Lupin (NSE:LUPIN, BOM:500257) has received the establishment inspection report (EIR) from the US Food and Drug Administration (US FDA) with a satisfactory voluntary action indicated (VAI) classification for its manufacturing facility in Somerset, New Jersey.
The inspection was conducted between April 13 and April 17, the pharmaceutical company said in a Wednesday filing to the Indian stock exchanges.
Under the VAI status, the regulator finds certain objectionable conditions or practices does not take or recommend administrative or regulatory action, according to the USFDA classification guidelines.
Lupin shares fell nearly 1% in Thursday's trade.